Publicerat: 2022-07-07 06:19:09

Cereno Scientific: First-patient-in and updated study timeline - Redeye

Redeye is encouraged by Cereno Scientific announcing first-patient-in for its phase II study with lead candidate CS1 in PAH. Further, the company updated its guidance on top-line data, now expected in Q1 2023 (Q4 2022).

Länk till analysen

Läs mer om Cereno Scientific AB